EC
LEGN icon

EntryPoint Capital’s Legend Biotech LEGN Stock Holding History

EntryPoint Capital’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,614
Closed -$248K – 826
2024
Q4 		$248K Buy
+7,614
New +$315K 0.1% 482
2024
Q3 		– Sell
-2,850
Closed -$126K – 1019
2024
Q2 		$126K Buy
2,850
+2,674
+1,519% +$123K 0.06% 680
2024
Q1 		$9.87K Buy
+176
New +$10.6K 0.01% 1238

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

EntryPoint Capital's LEGN Position: Q1 2025 in Review

EntryPoint Capital sold out of Legend Biotech (LEGN) in Q1 2025, closing a stake of 7,614 shares — an estimated $248K sold.

EntryPoint Capital first reported a position in LEGN in Q1 2024 and held it in 3 quarters. The position peaked at $248K in Q4 2024. 208 funds tracked by Wall St. Rank hold LEGN as of Q1 2025.

  • EntryPoint Capital reported no remaining Legend Biotech position as of Q1 2025 after selling out during the quarter.
  • EntryPoint Capital sold 7,614 Legend Biotech shares in Q1 2025, an estimated $248K.
  • EntryPoint Capital first reported a position in Legend Biotech in Q1 2024 and held it in 3 quarters.
  • EntryPoint Capital's Legend Biotech position peaked at $248K in Q4 2024.
  • 208 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2025.

Based on EntryPoint Capital's 13F filing for Q1 2025, filed 14 May 2025.